VANCOUVER, April 4 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, announced today that the first New Zealand patient was treated with Cook Medical Inc.'s Zilver(R) PTX(TM) drug-eluting peripheral stent in December 2007. A second patient was treated in February 2008. The Zilver PTX is the world's first drug-eluting stent for peripheral arterial disease (PAD) and was recently released for sale in certain regions worldwide including New Zealand.
Under the terms of its 1997 License Agreement with Cook, Angiotech is entitled to receive royalty payments upon the commercial sale of paclitaxel-eluting peripheral vascular stent products, including the Zilver PTX.
"Building on the success of our paclitaxel-eluting coronary stents, it is rewarding to see how our technology continues to be leveraged in other vascular indications. We hope that the Zilver PTX may provide a more long term treatment option for patients who suffer from peripheral arterial disease," said Dr. William Hunter, President and CEO of Angiotech.
The Zilver PTX is currently undergoing multiple clinical trials in the U.S., Japan, and the EU to assess product safety and efficacy.
About Zilver PTX
Cook Medical's Zilver PTX, a self-expanding nitinol stent, uses a
proprietary, polymer-free technology to coat the device with paclitaxel, an
antiproliferative drug that has been used successfully to reduce the risk
of renarrowing of arteries following angioplasty. In many cases, PAD
patients who have been treated with balloon angioplasty and stenting
experience restenosis, or renarrowing of the arteries, over time and must
undergo more invasive treatment such
|SOURCE Angiotech Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved